NewAmsterdam Pharma Income Statement (2021-2026) | NAMS

Income Statement Dec2021 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter) 11.33M38.29M38.33M38.53M38.72M38.57M41.49M44.47M44.49M44.30M54.52M55.66M55.87M55.60M57.14M57.92M
Revenue & cost
Revenue (Quarter) 8.63M1.72M2.94M0.80M1.40M2.28M29.11M12.77M2.98M19.14M0.35M0.03M3.04M3.70M
Operating items
Research & Development (Quarter) 40.42M34.34M43.37M41.29M42.43M38.38M35.70M34.90M44.75M27.52M30.97M38.59M38.01M41.67M
Selling, General & Administrative (Quarter) 8.06M9.86M9.13M10.59M14.45M16.48M18.41M21.11M27.15M27.26M24.52M27.42M23.45M26.89M
Other Operating Expenses (Quarter) -0.00M
Operating Expenses (Quarter) 48.48M44.20M52.50M51.88M56.88M54.85M54.11M56.00M71.90M54.78M55.49M66.01M61.46M68.56M
Operating Income (Quarter) -39.85M-42.48M-49.56M-51.07M-55.48M-52.58M-25.00M-43.23M-68.92M-35.63M-55.14M-65.98M-58.42M-64.86M
EBIT (Quarter) -39.85M-42.48M-49.56M-51.07M-55.48M-52.58M-25.00M-43.23M-68.92M-35.63M-55.14M-65.98M-58.42M-64.86M
Non-operating items
Interest & Investment Income (Quarter) 0.94M4.61M3.06M2.67M3.08M4.87M4.44M4.49M7.35M7.05M6.71M6.47M5.65M5.81M
Other Non Operating Income (Quarter) 3.07M-0.07M-3.15M5.22M-2.42M-0.99M4.68M-7.87M4.29M8.63M0.22M2.19M-1.61M-0.53M
Net income details
EBT (Quarter) -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M-74.92M-48.44M-64.14M
Tax Provisions (Quarter) -0.00M
Profit After Tax (Quarter) -42.02M-38.29M-47.13M-49.49M-93.77M-39.01M-16.65M-92.18M-39.56M-17.47M-72.00M-74.92M-49.01M-64.50M
Income from Continuing Operations (Quarter) -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M-74.92M-48.44M-64.14M
Consolidated Net Income (Quarter) -42.02M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M-74.92M-48.44M-64.14M
Income towards Parent Company (Quarter) -42.02M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M-74.92M-48.44M-64.14M
Net Income towards Common Stockholders (Quarter) -42.02M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M-74.92M-48.44M-64.14M
Additional items
EPS (Basic) (Quarter) -0.51-0.57-0.60-1.06-0.41-0.18-0.98-0.34-0.15-0.61-0.63-0.40-0.52
EPS (Diluted) (Quarter) -0.51-0.57-0.60-1.06-0.41-0.18-0.98-0.34-0.15-0.61-0.63-0.40-0.52
Shares Outstanding (Quarter) 24.13M81.56M81.63M82.06M82.47M82.16M88.38M94.71M94.75M94.36M116.12M118.56M119.00M118.42M121.72M123.37M
Shares Outstanding (Diluted) (Quarter) 11.33M18.97M81.63M82.06M82.47M82.16M88.38M94.71M94.75M94.36M116.12M118.56M119.00M118.42M121.72M123.37M
EBITDA (Quarter) -39.85M-42.48M-49.56M-51.07M-55.48M-52.58M-25.00M-43.23M-68.92M-35.63M-55.14M-65.98M-58.42M-64.86M
Interest Expenses (Quarter) 129.84M279.67M195.40M145.76M184.63M183.78M141.07M326.82M0.00M327.60M340.77M
Tax Rate (Quarter) 0.01